<DOC>
	<DOCNO>NCT01439126</DOCNO>
	<brief_summary>The purpose study determine long-term efficacy safety KAPVAY™ ( clonidine hydrochloride ) extended-release child adolescent Attention Deficit Hyperactivity Disorder ( ADHD )</brief_summary>
	<brief_title>Efficacy &amp; Safety KAPVAY™ Extended-Release Children &amp; Adolescents With Attention Deficit Hyperactivity Disorder</brief_title>
	<detailed_description />
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<mesh_term>Clonidine</mesh_term>
	<criteria>Male female , age 6 17 year inclusive Subject well parent/guardian able sign inform assent consent form Subject meet Diagnostic Statistical Manual Mental Disorders 4th edition , Text Revision ( DSMIVTR ) criteria primary diagnosis Attention Deficit Hyperactivity Disorder ( ADHD ) , combine subtype , hyperactive/impulsive subtype , inattentive subtype base detailed psychiatric evaluation use Shorter version KiddieSchedule Affective Disorders SchizophreniaPresent Lifetime ( MINIKid ) DSMIV TR base checklist ADHD Subject minimum Attention Deficit Hyperactivity DisorderRating Scale4th edition ( clinician version ) total score 28 baseline ( Visit 2 ) Subject minimum Clinical Global ImpressionsSeverity Illness Scale 4 baseline ( Visit 2 ) Subject able swallow intact tablet base upon interview screening procedure Subject function ageappropriate level intellectually estimate intelligence quotient least 70 base interview history Subject parent/guardian understand , willing , fully comply study requirement , procedure , restriction define protocol Subject supine stand blood pressure measurement within 95th percentile age , gender , height If female experience menarche , must negative serum beta human chorionic gonadotropin pregnancy test screening ( Visit 1 ) , negative urine pregnancy test baseline ( Visit 2 ) , agree abstinent sexual activity could result pregnancy , use acceptable contraceptive throughout period study drug exposure 30 day last dose study drug Subject current comorbid psychiatric condition ( except oppositional defiant disorder ) control ( require prohibit medication behavioral modification program ) uncontrolled . Subject condition illness include clinically significant abnormal screening ( Visit 1 ) laboratory value , opinion investigator , represent inappropriate risk subject and/or could confound interpretation study Subject know history presence structural cardiac abnormality , serious heart rhythm abnormality , syncope , cardiac conduction problem ( eg , clinically significant heart block ) , exerciserelated cardiac event include syncope presyncope , clinically significant bradycardia Subject pregnant nursing ( lactate ) deem investigator staff significant risk become pregnant . Subject orthostatic hypotension know history control uncontrolled hypertension Subject clinically significant electrocardiogram ( ECG ) finding judge investigator consideration central ECG laboratory 's interpretation . Current use prohibit medication medication include herbal supplement affect blood pressure , heart rate , central nervous system effect , affect cognitive performance sedate antihistamine decongestant sympathomimetics ( inhaled bronchodilator permit ) ; history chronic use sedate medication ( ie , antihistamine ) violation protocol specify washout criterion baseline ( Visit 2 ) Subject use investigational product within 30 day prior baseline ( Visit 2 ) Subject significantly overweight base body mass Index ( BMI ) ageand genderspecific chart compile Center Disease Control Prevention . Significantly overweight define BMI ≥95th percentile Subject significantly underweight base BMI ageand genderspecific chart compile Center Disease Control Prevention . Subject know suspect allergy , hypersensitivity , clinically significant intolerance clonidine hydrochloride Clinically important abnormality drug alcohol screening ( exclude subject 's current ADHD stimulant applicable ) screening ( Visit 1 ) Subject history alcohol , substance abuse , dependence define DSMIVTR ( exception nicotine ) within last 6 month . Subject currently consider suicidal risk opinion investigator , previously make suicide attempt , prior history , currently demonstrate active suicidal ideation base Columbia Suicide Severity Rating Scale ( CSSRS ) . Subject history failure respond adequate trial alpha 2agonist stimulant nonstimulant drug alone combination treatment ADHD . Subject history seizure disorder ( single childhood febrile seizure occur age 3 year ) presence serious tic disorder ( include Tourette syndrome ) Subjects treat immediate release clonidine and/ KAPVAY™ guanfacine ( INTUNIV™ ) within past 30 day</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Attention Deficit Hyperactivity Disorder</keyword>
</DOC>